| Description: |
GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(V600E) tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% For 8 hours) and improved survival compared with mutant KRAS-expressing tumors. Despite the involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression was observed For some KRAS-mutant tumors following GDC-0879 administration. Moreover, striking differences were noted For RAF and MEK inhibition across a panel of 130 tumor cell lines. Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity. These data suggest that GDC-0879-induced signaling changes are dependent on the point of oncogenic activation within the RAS network. Taken together, these studies increase our understanding of the molecular determinants For antitumor efficacy resulting from RAF pathway inhibition and have implications For therapeutic intervention in the clinic.
For the detailed information about the solubility of GDC-0879 in water, the solubility of GDC-0879 in DMSO, the solubility of GDC-0879 in PBS buffer, the animal experiment（test） of GDC-0879,the in vivo,in vitro and clinical trial test of GDC-0879,the cell experiment（test） of GDC-0879,the IC50, EC50 and Affinity of GDC-0879, please contact DC Chemicals. |
